文献速递遗传性与小管间质肾病急性肾损伤肾小球疾病

抗刷状缘抗体病的临床病理特征

Clinicopathologic Features of Antibrush Border Antibody Disease.
PubMed 文献 · Kidney Int Rep · 2023-11-19

该病例系列纳入67例经肾活检确诊的抗刷状缘抗体病(ABBA)患者,中位年龄72岁,多为男性。94.2%见LRP2阳性肾小管基底膜沉积,56.7%合并第二种肾病。随访患者中29.4%缓解、70.6%无应答、52.8%需透析或死亡,未治疗者风险最高。

要点

  • ABBA多见于老年男性,常合并其他肾病,尤其伴大量蛋白尿的肾小球疾病。
  • LRP2阳性肾小管基底膜沉积是特征性病理表现,见于94.2%患者。
  • 总体预后差,但免疫抑制治疗可能获益,未治疗者风险最高。

核心结论

  • ABBA是一种罕见的自身免疫性肾小管间质肾病,常与其他肾病共存,总体预后差但免疫抑制治疗可能有潜在获益。

研究设计与样本

  • 病例系列研究,纳入67例经肾活检的ABBA患者(65例自体肾、2例移植肾),51例有随访数据。

主要发现

  • 患者以男性为主,中位年龄72岁;中位血清肌酐2.7 mg/dl,蛋白尿2.8 g/day,三分之二患者有血尿。
  • 94.2%患者见肾小管损伤伴LRP2阳性肾小管基底膜沉积。
  • 56.7%患者合并第二种肾病,包括足细胞病、膜性肾病、IgA肾病、糖尿病肾小球病、狼疮性肾炎、新月体性肾小球肾炎、肾小管间质性肾炎及淋巴瘤累及。
  • 随访患者中29.4%达到缓解,70.6%无应答,52.8%需透析或死亡;未治疗患者风险最高。

临床怎么用

  • 对老年男性出现肾小管间质损伤且合并肾小球疾病时应考虑ABBA,肾活检免疫染色LRP2有助诊断。
  • 免疫抑制治疗可能改善预后,但需权衡风险,尤其未治疗者预后最差。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Antibrush border antibody disease (ABBA) is an autoimmune tubulointerstitial kidney disease that primarily affects older individuals and results in progressive kidney failure. It is rare with only 20 reported cases. Here, we describe a case series to further define the clinicopathologic spectrum and natural history, and to inform management. METHODS: We identified 67 patients with ABBA who underwent kidney biopsy, including 65 native and 2 transplants. Demographics, clinical findings, and laboratory data were obtained. Histopathologic data included light microscopy, immunofluorescence, electron microscopy and immunostaining for LRP2, CUBN, and AMN. Follow-up data, including treatment(s), laboratory values, and outcomes, were available from 51 patients. RESULTS: Patients with ABBA were predominantly male with a median age of 72 years. Median serum creatinine was 2.7 mg/dl, proteinuria was 2.8 g/day, and hematuria was present in two-thirds of the patients. Tubular injury with LRP2-positive tubular basement membrane (TBM) deposits were seen in 94.2% of patients. Thirty-eight patients (56.7%) had a second kidney disease, commonly glomerular diseases with high-grade proteinuria. These diseases included podocytopathies, membranous nephropathy (MN), IgA nephropathy, diabetic glomerulopathy, lupus nephritis (LN), crescentic glomerulonephritis (GN), tubulointerstitial nephritis, and involvement by lymphoma. The majority of patients were treated with immunosuppression. Of those patients with follow-up, 29.4% achieved remission, 70.6% had no response, and 52.8% required dialysis or were deceased. Untreated patients were at the highest risk. CONCLUSION: ABBA is a rare autoimmune kidney disease that often occurs with other kidney diseases. Although the overall prognosis of ABBA is poor, there is potential benefit from immunosuppression.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Murphy JD, Caza TN, Cassol CA, et al. Clinicopathologic Features of Antibrush Border Antibody Disease. Kidney Int Rep. 2023. PMID: 38344713. doi:10.1016/j.ekir.2023.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。